{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058627","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.460897+00:00","generated_at":"2026-06-08T22:21:17.685748+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Clearside Biomedical licenses SCS Microinjector to BioCryst for avoralstat in DME","bullets":["Clearside granted BioCryst exclusive worldwide license to use SCS Microinjector for avoralstat in diabetic macular edema.","Upfront fee of $5.0 million; eligible for up to $30.0 million in clinical/regulatory milestones and $47.5 million in sales-based milestones.","Tiered mid-single digit royalties on annual global net sales, highest rate on sales over $1.5 billion.","BioCryst responsible for all development, regulatory, and commercialization; Clearside to supply SCS Microinjectors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058627","json":"https://secwatch.observer/filing/0000950170-23-058627.json","markdown":"https://secwatch.observer/filing/0000950170-23-058627.md","text":"https://secwatch.observer/filing/0000950170-23-058627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023058627/0000950170-23-058627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023058627/clsd-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:21:17.685748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"599f45c697aa78328dc5387fd16cb267bb768c18","claim":"Clearside Biomedical, Inc. entered into License Agreement with BioCryst Pharmaceuticals, Inc. valued at Upfront license fee of $5.0 million, clinical and regulatory milestones up to $30.0 million, sales-b (effective 2023-11-01).","evidence_excerpt":"On November 1, 2023, Clearside Biomedical, Inc. (the “ Company ”) entered into a license agreement (the “ License Agreement ”) with BioCryst Pharmaceuticals, Inc. (“ BioCryst ”) pursuant to which the Company granted BioCryst an exclusive, worldwide and sublicensable license to the Company’s SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and prevention of diabetic macular edema (“ DME ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023058627/0000950170-23-058627-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"BioCryst Pharmaceuticals, Inc."},{"label":"Value","value":"Upfront license fee of $5.0 million, clinical and regulatory milestones up to $30.0 million, sales-b"},{"label":"Effective","value":"2023-11-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}